Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and European Society for Immunodeficiencies (ESID), X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or Autosomal Recessive Agammaglobulinemia~* Chest X-ray or CT scan obtained within 1 year prior to enrolment~Exclusion Criteria:~* Newly diagnosed PID, i.e. subjects who have not previously received immunoglobulin replacement therapy~* Ongoing serious bacterial infection at the time of screening~* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma~* Allergic or other severe reactions to immunoglobulins or other blood products associated with high anti-IgA~Additional criteria may apply and examination by an investigator is required to determine eligibility.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).